The curious immunology behind the UK's surprise AstraZeneca dosing plan
As expected, UK regulators authorized AstraZeneca’s Covid-19 vaccine on Wednesday. What was less expected were the instructions authorities gave when OKing it: People could receive the two doses of the vaccine as many as 12 weeks apart — three times as long as the period studied in the company’s clinical trials.
The decision set off a debate. Some scientists and epidemiologists said it could put more jabs in more arms faster, with new evidence suggesting that the vaccine begins to offer protection after just a single dose. Others pointed out there was no direct evidence giving the vaccine in this way would work, adding more questions to a vaccine that has already spent two months mired in controversy.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,500+ biopharma pros reading Endpoints daily — and it's free.